Steady But Slow: Future Outlook for Investment

Update: 2024-10-24

Description

In this episode, we’re talking money.

The guests in this discussion recognize that the economic climate has been different (and more chaotic) in last three to four months, but expect a steady but slow improvement as we move into the new year.

This episode reviews 2024’s investment landscape and the policies influencing investment going into 2025.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

Konstantina Katcheves, Senior Vice President, Innovative Medicines Global Business Development and Acquisitions, Teva Pharmaceuticals

Sanskriti Thakur, Chairwoman, TOWER Capital

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

51%: The Untapped Market

2024-11-2113:12

RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

2024-11-2015:07

AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More

2024-11-1315:18

Investing in AI: Benefits, Regulatory Challenges

2024-11-0713:08

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

2024-11-0616:41

Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More

2024-10-3017:43

Steady But Slow: Future Outlook for Investment

2024-10-2416:21

Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More

2024-10-2318:35

Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More

2024-10-1615:44

How AI Could Ease Tension in Clinical Trials

2024-10-1012:51

BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More

2024-10-0916:40

BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day

2024-10-0217:44

AI Return on Investment: Just Because We Can, Should We?

2024-09-2618:28

Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval

2024-09-2519:57

Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024

2024-09-1817:56

AI Promises: Funding Data Literacy and Reality First

2024-09-1219:28

BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement

2024-09-1116:33

Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases

2024-09-0412:50

Future-Proofing: Inclusive and Protective Patient Strategies

2024-08-2925:15

A Tough Ending, New Beginnings and China-U.S. Biopharma Relations

2024-08-2815:21

00:00

Steady But Slow: Future Outlook for Investment

#box-pro-ellipsis-173224771140790{-webkit-line-clamp:2;}Steady But Slow: Future Outlook for Investment

Steady But Slow: Future Outlook for Investment

BioSpace

Steady But Slow: Future Outlook for Investment